FMS1 Antibody

What is the FMS1 antibody and what cellular receptor does it target?

The FMS1 antibody targets CD115, also known as c-fms, which functions as the receptor for macrophage colony stimulating factor (M-CSF) or colony stimulating factor-1 (CSF-1) . This receptor is a transmembrane protein that belongs to the immunoglobulin family and plays a crucial role in monocyte/macrophage biology . Structurally, CD115 is a 150 kDa product of the c-fms gene and functions as a tyrosine kinase transmembrane receptor within the CSF1/PDGF receptor family of tyrosine-protein kinases .

The receptor serves as a cell-surface receptor for both CSF1 and IL34, playing an essential role in regulating the survival, proliferation, and differentiation of hematopoietic precursor cells, particularly cells of the mononuclear phagocyte lineage . The signaling cascade initiated by ligand binding to CD115 involves receptor oligomerization and transphosphorylation, which ultimately regulates macrophage development and function.

Several monoclonal antibodies against this receptor have been developed for research purposes, with the AFS98 clone being commonly used in experimental settings to study monocyte and macrophage biology in mice .

Which cell types express the CD115/c-fms receptor in normal tissue?

The CD115 (c-fms) receptor exhibits a restricted expression pattern primarily associated with the mononuclear phagocyte lineage . Specifically, the receptor is expressed by monocytes, macrophages, osteoclasts, and some epithelial cells . This selective expression makes CD115 an important marker for identifying and studying cells of the monocyte/macrophage lineage.

In normal human peripheral blood, CD115 expression is largely restricted to monocytes, while in bone marrow, the receptor marks cells committed to the mononuclear phagocyte developmental pathway . The restricted expression pattern of CSF-1 receptors to the mononuclear phagocyte lineage has been confirmed through flow cytometric techniques using monoclonal antibodies targeting the extracellular domain of the human c-fms proto-oncogene product .

Importantly, the expression of CD115 can be regulated by various stimuli, including exposure to its ligand CSF-1, which induces receptor downmodulation as part of normal receptor turnover and signaling regulation . This dynamic regulation of receptor expression is critical for normal myeloid cell development and function.

What is the functional significance of CSF-1 signaling through the CSF-1 receptor?

CSF-1 signaling through the CSF-1 receptor (CD115) regulates multiple critical aspects of mononuclear phagocyte biology, primarily controlling the proliferation and differentiation of cells in the monocytic lineage . This signaling axis is essential for the development of the mononuclear phagocyte system, which includes monocytes, macrophages, and osteoclasts.

At the molecular level, binding of CSF-1 to its receptor activates the receptor's intrinsic tyrosine kinase activity through a process of oligomerization and transphosphorylation . This activation initiates several downstream signaling cascades that regulate gene expression patterns controlling cell survival, proliferation, and differentiation. The functional importance of this pathway is underscored by the finding that mutations in the gene encoding CSF1R have been associated with a predisposition to myeloid malignancies .

Beyond normal development, CSF-1 signaling through CD115 promotes the release of proinflammatory chemokines in response to various stimuli, highlighting its role in immune function and inflammatory responses . The regulatory mechanisms controlling CD115 expression and signaling are therefore critical for both normal myeloid development and appropriate immune responses to pathogens and tissue damage.

How does epitope specificity affect the functionality of different FMS1 antibody clones?

The epitope specificity of FMS1 antibodies critically determines their functionality in both research and potential clinical applications. Different antibody clones recognize distinct epitopes on the CD115 receptor, which can significantly affect binding characteristics, receptor function modulation, and downstream signaling effects . For instance, antibodies targeting the extracellular domain of the receptor, like clone AFS98, are particularly valuable for flow cytometric analysis because they recognize accessible epitopes on intact cells .

The specificity of epitope recognition also impacts the ability of antibodies to detect the receptor in different conformational states. Some antibodies may preferentially bind to the unoccupied receptor, while others may recognize the ligand-bound form or both forms . This distinction is particularly important when developing diagnostic assays, such as those for sFlt-1 (a soluble form of FMS-like tyrosine kinase-1), where antibodies capable of recognizing both free and bound forms offer enhanced diagnostic capabilities .

Moreover, epitope specificity determines whether an antibody will exhibit functional effects, such as blocking ligand binding or receptor dimerization. Antibodies targeting epitopes involved in ligand recognition may function as competitive antagonists, while those binding to regions involved in receptor dimerization might affect signal transduction without interfering with ligand binding. These distinctions are crucial when selecting antibodies for specific research applications or therapeutic development.

What approaches are used to optimize FMS1 antibody titration for flow cytometry applications?

Optimizing FMS1 antibody titration for flow cytometry requires a systematic approach to determine the minimal concentration that provides maximum signal-to-noise ratio. The AFS98 monoclonal antibody, which reacts with mouse CD115, can be used at ≤0.125 μg per test for flow cytometric analysis of bone marrow-derived macrophages . Similarly, for thioglycolate-elicited peritoneal exudate cells, the same antibody can be used at ≤0.06 μg per test .

A standard titration protocol involves:

• Preparing serial dilutions of the antibody starting from the manufacturer's recommended concentration

• Staining a fixed number of cells (typically 10^5 to 10^8 cells/test) with each dilution

• Analyzing signal intensity and background staining by flow cytometry

• Determining the optimal concentration that maximizes specific staining while minimizing background

For accurate titration, researchers should use a cell population with known expression of CD115, such as bone marrow-derived macrophages or thioglycolate-elicited peritoneal exudate cells for mouse studies . The staining should be performed in a final volume of 100 μL, and appropriate isotype controls should be included to assess background staining.

It is important to note that optimal antibody concentration may vary depending on the specific application, cell type, sample preparation method, and flow cytometer settings. Therefore, antibody titration should be performed for each new experimental setup or when changing any parameters of the staining protocol.

What mechanisms contribute to the downmodulation of CSF-1 receptors after ligand binding?

The downmodulation of CSF-1 receptors (CD115) following ligand binding involves several coordinated molecular mechanisms that regulate receptor abundance and signaling duration. Upon binding of CSF-1 to CD115, the receptor undergoes ligand-induced downmodulation, a process that can also be mimicked by phorbol esters, which are inducers of protein kinase C . This downmodulation is critical for regulating the sensitivity of cells to CSF-1 and preventing excessive signaling.

The primary mechanisms contributing to CSF-1 receptor downmodulation include:

• Receptor-mediated endocytosis: Upon ligand binding, the receptor-ligand complex is internalized through clathrin-coated pits into endosomes.

• Ubiquitination and lysosomal degradation: Following internalization, the receptor is ubiquitinated, targeting it for degradation in lysosomes rather than recycling to the cell surface.

• Protein kinase C-mediated phosphorylation: Activation of protein kinase C, either directly by phorbol esters or indirectly through receptor signaling, leads to phosphorylation of the receptor, which can accelerate its internalization and degradation.

• Transcriptional regulation: Prolonged exposure to CSF-1 can also lead to changes in receptor gene expression, further modulating surface receptor levels.

These mechanisms collectively ensure proper regulation of CSF-1 signaling, which is essential for normal myeloid development and function. Dysregulation of these processes can contribute to abnormal myeloid cell development and function, potentially contributing to myeloid malignancies and other disorders .

How do somatic mutations affect the breadth and potency of monoclonal antibodies?

Somatic mutations play a critical role in determining the breadth and potency of monoclonal antibodies, as demonstrated by studies on broadly neutralizing antibodies against influenza viruses . The evolutionary pathways through which antibodies develop broader recognition capabilities often involve specific patterns of somatic hypermutation that enhance affinity while expanding epitope recognition.

Analysis of antibody lineages has revealed that unmutated common ancestors (UCAs) often exhibit restricted binding specificities, which gradually expand through somatic mutations . For example, the FY1 antibody lineage initially neutralized only group 1 influenza viruses, but through somatic mutations at branching points in its evolutionary history, some variants gained the ability to neutralize group 2 viruses as well . Similarly, the FI6 antibody lineage evolved from a group 1-specific UCA to produce variants capable of neutralizing both group 1 and group 2 viruses through independent pathways of somatic mutations .

The critical role of somatic mutations is further emphasized by antibody optimization studies. MEDI8852, an optimized version of the FY1 antibody, was developed through parsimonious mutagenesis of the complementarity determining regions (CDRs) combined with reversion of unnecessary somatic mutations in the frameworks . This optimization resulted in a 14-fold improvement in Fab affinity to H3 HA and a 5-fold improvement in affinity to H1 HA proteins .

These findings suggest that strategic approaches to antibody engineering, based on understanding natural somatic mutation pathways, can yield antibodies with enhanced breadth and potency for research and therapeutic applications.

What are the recommended fixation protocols for cell samples when using FMS1 antibodies?

Proper fixation of cell samples is crucial for maintaining epitope integrity and antibody binding when using FMS1 antibodies in flow cytometry and other applications. For optimal results with CD115 (c-fms) antibodies, samples can be stored in IC Fixation Buffer (100 μL cell sample + 100 μL IC Fixation Buffer) or 1-step Fix/Lyse Solution for up to 3 days in the dark at 4°C with minimal impact on brightness and FRET efficiency/compensation .

When performing intracellular staining or when extended sample storage is necessary, it is important to select fixation protocols that preserve the target epitope while maintaining cellular integrity. The choice between different fixation methods should consider:

• The cellular localization of the epitope (surface vs. intracellular)

• The nature of the epitope (conformational vs. linear)

• The intended downstream application (flow cytometry, immunohistochemistry, etc.)

• The need for simultaneous detection of other markers

For multicolor flow cytometry applications, it is advisable to first optimize fixation conditions for each antibody individually before combining them in a single panel. This ensures that the fixation protocol does not differentially affect the various epitopes being detected.

It is worth noting that some epitopes may be fixation-sensitive, so if signal loss is observed after fixation, alternative fixing agents or concentrations should be tested, or samples should be analyzed fresh without fixation when possible.

How should researchers design appropriate controls for detecting c-fms expression in leukemic blast cells?

Designing appropriate controls for detecting c-fms expression in leukemic blast cells requires a comprehensive approach to ensure accurate identification of positive populations and meaningful interpretation of results. Based on studies of c-fms expression in acute myeloid leukemia (AML), several control strategies are essential .

First, appropriate isotype controls matched to the primary antibody's isotype, species, and fluorochrome should be included to establish background fluorescence levels and identify non-specific binding. For multicolor flow cytometry, fluorescence minus one (FMO) controls are valuable for setting accurate gates, especially when analyzing heterogeneous populations like leukemic blasts.

Positive cellular controls are equally important. Normal peripheral blood monocytes serve as excellent positive controls for c-fms expression, as they consistently express the receptor . Including these cells in each experiment provides a reference for positive staining intensity. Additionally, negative cellular controls such as lymphocytes, which do not express c-fms, help confirm the specificity of staining .

Functional validation controls can further strengthen the reliability of results. For instance, demonstrating receptor downmodulation upon incubation with either recombinant CSF-1 or phorbol esters confirms that the detected receptors have functional ligand-binding sites and respond appropriately to stimuli . This functional validation is particularly valuable when studying potentially aberrant receptor expression in leukemic cells.

Finally, when examining leukemic samples, correlation with other lineage markers and morphological features is essential for accurate interpretation. Studies have shown that c-fms expression is highest in leukemic blasts with monocytic features but can also be detected on blasts with granulocytic differentiation .

What are the optimal parameters for flow cytometric analysis using FMS1 antibodies?

Optimal flow cytometric analysis using FMS1 antibodies requires careful consideration of multiple technical parameters to ensure accurate and reproducible results. For PE-Cyanine7 conjugated CD115 antibodies (clone AFS98), the optimal excitation occurs at approximately 496-566 nm, with emission at 785 nm . For APC-conjugated variants, excitation at 633-647 nm and emission at 660 nm are optimal, typically requiring a red laser for detection .

Sample preparation significantly impacts results. The antibody concentration should be carefully titrated, with recommended starting points of ≤0.125 μg per test for bone marrow-derived macrophages and ≤0.06 μg per test for thioglycolate-elicited peritoneal exudate cells . A test is defined as the amount of antibody that will stain a cell sample in a final volume of 100 μL, with cell numbers typically ranging from 10^5 to 10^8 cells/test .

Instrument settings should be optimized using single-stained controls to establish appropriate compensation when multiple fluorochromes are used. Voltage settings should be adjusted to position the negative population in the first decade of the logarithmic scale while ensuring that positive populations are on scale.

Analysis gates should be established using forward and side scatter to identify viable cells and exclude debris, followed by specific gating strategies based on the experimental question. For studies of myeloid cells, additional markers such as CD11b and Gr-1 may be included to further define populations of interest .

For long-term reproducibility, standardization beads should be used to ensure consistent instrument performance across experiments. Detailed records of all instrument settings, gating strategies, and control results should be maintained to facilitate troubleshooting and ensure experimental consistency.

How can researchers develop a sandwich assay for detecting sFlt-1 in biological samples?

Developing a sandwich assay for detecting soluble FMS-like tyrosine kinase-1 (sFlt-1) in biological samples requires careful selection of antibodies and optimization of assay conditions. A successful approach has been described using a double monoclonal antibody sandwich assay format .

The first critical step is selecting appropriate antibody pairs that recognize distinct, non-overlapping epitopes on the sFlt-1 molecule. The capture antibody should be chosen for its ability to bind sFlt-1 in both free and bound forms, maximizing the detection of total sFlt-1 in the sample . This antibody is typically immobilized on a solid support, such as paramagnetic particles, to facilitate separation during the assay procedure.

The detection antibody should bind to a different epitope on sFlt-1 and be conjugated to a detection system that provides sensitive and quantitative signal output. Chemiluminescent labels, such as acridinium, have been successfully used for this purpose . The selection of detection system should consider the expected concentration range of sFlt-1 in the biological samples of interest and the available detection instrumentation.

Assay optimization involves:

• Determining optimal antibody concentrations through checkerboard titration

• Establishing appropriate sample dilution factors to ensure measurements within the linear range of the assay

• Optimizing incubation times and temperatures for each step

• Developing effective washing procedures to minimize background signals

• Creating a standard curve using purified sFlt-1 protein at known concentrations

The resulting optimized assay should be validated for specificity, sensitivity, precision, accuracy, and range. Cross-reactivity testing with related proteins is particularly important to ensure specificity for sFlt-1. The validated assay can then be automated for high-throughput applications, providing a fast and reliable method for quantifying sFlt-1 in various biological samples .

What patterns of c-fms expression differentiate normal mononuclear phagocytes from leukemic cells?

The expression patterns of c-fms (CD115) provide valuable insights for distinguishing normal mononuclear phagocytes from leukemic cells. In normal human tissues, c-fms expression is tightly restricted to the mononuclear phagocyte lineage, including monocytes, macrophages, and their precursors . This lineage-specific expression makes c-fms a useful marker for identifying cells committed to the monocyte/macrophage developmental pathway.

In contrast, leukemic blast cells show variable and often aberrant expression patterns of c-fms. Studies using monoclonal antibodies to the human CSF-1 receptor have revealed that approximately 30% of pediatric acute myeloid leukemia (AML) cases and 15% of adult AML cases express detectable levels of c-fms on their blast cells . This variability in expression can be clinically significant and may correlate with specific disease characteristics.

The relationship between c-fms expression and leukemic cell differentiation follows particular patterns:

These distinct expression patterns suggest that c-fms detection using specific monoclonal antibodies can contribute to the immunophenotypic characterization of leukemic cells, potentially aiding in diagnosis, classification, and therapeutic decision-making.

How does the presence of specific glycans affect antibody binding to target epitopes?

The presence of specific glycans can significantly impact antibody binding to target epitopes through several mechanisms, creating important considerations for antibody development and application. Glycosylation patterns can either facilitate or hinder antibody-epitope interactions, depending on their location and structure.

A notable example comes from studies of antibodies targeting the hemagglutinin (HA) stem region of influenza viruses. The antibody response to the HA stem region of group 2 HAs is less frequent than to group 1 HAs, possibly due to the presence of a conserved glycan bound to N38 in HA1 . This glycan appears to shield access to the most conserved sites in the HA stem, effectively masking potential epitopes from antibody recognition . This glycan-mediated epitope shielding represents a natural immune evasion strategy employed by viruses.

The impact of glycosylation extends beyond simple epitope masking. Glycans can also:

• Alter protein conformation, indirectly affecting epitope structure and accessibility

• Interact directly with antibody paratopes, either enhancing or interfering with binding

• Modify the electrostatic and hydrophobic properties of the protein surface

• Create novel epitopes that are glycan-dependent or glycan-protein combined structures

These glycosylation effects have important implications for antibody development strategies. When targeting glycosylated proteins like cell surface receptors, researchers must consider whether their antibodies should be glycan-sensitive or glycan-insensitive, depending on the specific application. For therapeutic antibodies, glycan-insensitive binding may be preferable to avoid potential escape through glycosylation changes, while for certain diagnostic applications, glycan-sensitive antibodies might offer higher specificity.

What is the significance of c-fms genetic structure in understanding receptor expression and function?

The genetic structure of c-fms plays a crucial role in understanding receptor expression patterns, regulation mechanisms, and functional implications in both normal and pathological contexts. Analysis of the c-fms locus has revealed several important structural features that influence its expression and function.

The c-fms gene contains coding exons distributed over approximately 32 kb of genomic sequence, with additional regulatory elements extending 50 kb upstream of the first coding exon . Notably, sequences representing the terminal 112 untranslated nucleotides of c-fms mRNA map 26 kb 5' to the first coding exon, suggesting that at least one c-fms promoter is separated from the coding region by a substantial distance . This complex genomic organization allows for sophisticated transcriptional regulation, potentially enabling tissue-specific and developmental stage-specific expression patterns.

Despite the frequent dysregulation of c-fms expression in myeloid leukemias, Southern blotting analyses of DNA from 47 cases of acute myeloid leukemia demonstrated no rearrangements within the 32 kb of genomic sequences containing CSF-1 receptor coding exons or in the 50 kb upstream of the first coding exon . This suggests that altered expression in leukemic cells likely results from changes in transcriptional regulation rather than structural gene alterations.

The genetic structure also influences the potential for alternative splicing, which can generate receptor variants with distinct functional properties. Understanding these structural aspects of the c-fms gene provides insights into the mechanisms controlling receptor expression and function in both normal myeloid development and pathological conditions such as leukemia and other myeloid disorders.

What role does HMGB1 play in modulating immune responses, and how can HMGB1-targeting antibodies affect this process?

High mobility group box 1 (HMGB1) is a critical mediator in the immune system that can significantly influence both inflammatory responses and immune suppression. Released from damaged tissues following trauma, HMGB1 participates in complex signaling pathways that can either enhance or suppress immune functions depending on the context .

In trauma-induced immune suppression, HMGB1 plays a particularly important role. Using an established mouse model of peripheral tissue trauma, researchers have demonstrated that HMGB1 released after tissue injury contributes to signaling pathways that lead to attenuation of T-lymphocyte responses and enhancement of myeloid-derived suppressor cell expansion . These myeloid-derived suppressor cells (MDSCs), characterized by their CD11b+Gr-1+ phenotype, accumulate in the spleen following tissue trauma and actively suppress T-cell functions .

Anti-HMGB1 monoclonal antibodies have emerged as potential therapeutic tools to modulate these immune responses. Treatment with anti-HMGB1 monoclonal antibodies has been shown to ameliorate trauma-induced immune suppression by:

• Preventing the attenuation of T-cell responses typically observed after trauma

• Reducing the accumulation of CD11b+Gr-1+ myeloid-derived suppressor cells in the spleen

• Restoring immune competence, potentially reducing susceptibility to secondary infections after trauma

These findings suggest that HMGB1 represents a key molecular link between tissue damage and subsequent immune dysregulation. By targeting HMGB1 with specific monoclonal antibodies, it may be possible to prevent the cascade of events leading to post-trauma immune suppression, potentially improving outcomes in trauma patients who are at high risk of secondary infections due to compromised immune function.

How might next-generation antibody engineering approaches improve FMS1-targeting therapies?

Next-generation antibody engineering approaches offer promising avenues for enhancing FMS1-targeting therapies through increased specificity, improved functionality, and optimized pharmacokinetic properties. Learning from successful antibody optimization efforts, such as the development of MEDI8852 from the FY1 antibody, several strategic approaches emerge for future research .

Parsimonious mutagenesis of complementarity determining regions (CDRs) combined with reversion of unnecessary somatic mutations in framework regions has proven highly effective in improving antibody affinity while maintaining specificity . This approach could be applied to FMS1 antibodies to enhance binding to specific epitopes on the CD115 receptor, potentially allowing for more precise modulation of receptor function.

Another promising direction involves developing bispecific antibodies that simultaneously target CD115 and another relevant molecule, such as a co-receptor or downstream signaling component. This approach could enable more selective targeting of specific cell populations or signaling pathways, potentially reducing off-target effects and enhancing therapeutic efficacy.

Antibody-drug conjugates (ADCs) represent another powerful approach, particularly for targeting leukemic cells expressing CD115. By conjugating cytotoxic payloads to FMS1 antibodies, researchers could develop highly targeted therapies for CD115-positive malignancies while sparing normal cells with lower receptor expression.

Finally, engineering antibodies with modified Fc regions could tailor their effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC), to specific therapeutic contexts. This approach might be particularly valuable for developing immunotherapies that harness the immune system to eliminate malignant cells expressing CD115.